We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Study Finds Hidden Mpox Infections May Drive Ongoing Spread

By LabMedica International staff writers
Posted on 15 May 2026

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. More...

The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists. Defining this pathway is important for directing testing within sexual health services. New reserach now indicates that asymptomatic, undiagnosed infections are common and likely contributed substantially to spread.

Kaiser Permanente led an analysis that leveraged specimens and data already generated in clinical care to characterize silent transmission. Investigators tested rectal swabs—originally collected for routine sexually transmitted disease screening—for mpox, monitored electronic health records for new diagnoses among health plan members, and applied viral genomic sequencing to reconstruct transmission patterns. This combined screening, surveillance, and phylogenetic approach was designed to capture infections that standard symptom-driven case finding would miss.

The study evaluated nearly 8,000 men who have sex with men (MSM) in Southern California during the summer and early fall of 2024. While classic symptoms of mpox include fever, chills, myalgias, lymphadenopathy, and a painful rash, the cohort strategy focused on detecting infections irrespective of clinical presentation. Concurrent monitoring of electronic health records among Kaiser Permanente Southern California enrollees enabled linkage of undiagnosed infections to subsequent case ascertainment.

Testing of repurposed rectal swabs identified asymptomatic infections in approximately 1% of MSM who were unaware of their status. Modeling based on these data indicated that only about one in 33 infections was diagnosed during the study window. Genomic analyses showed transmission patterns inconsistent with a scenario in which the small fraction of diagnosed cases accounted for all onward spread, underscoring the contribution of undetected infections. The study also found that vaccination reduced the risk of being diagnosed with mpox by 78% and reduced the overall risk of infection by 50%.

The work was conducted by Kaiser Permanente in collaboration with the University of California, Berkeley School of Public Health and is published in Nature Communications. The authors noted that increasing vaccination coverage could play a significant role in controlling ongoing transmission.

“We have not known how mpox is transmitted, and why the cases seem to have very few connections to other cases. However, these findings help resolve a fundamental question in the epidemiology of mpox by suggesting that infected people pose a risk of transmitting the disease to others even in the absence of clinical symptoms,” said Sara Y. Tartof, scientist with the Kaiser Permanente Southern California Department of Research & Evaluation.

"We used the specimens from routine testing for other sexually transmitted diseases to test for mpox and found roughly 1% of men had asymptomatic infections without knowing it. From the testing, we estimated that only about one in every 33 infections gets diagnosed and confirmed this by analyzing transmission patterns revealed by viral genomic sequences,” said Joseph A. Lewnard, associate professor of epidemiology at the UC Berkeley School of Public Health.

Related Links
Kaiser Permanente 
UC Berkeley School of Public Health


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Originally designed for lung cancer detection and resistance monitoring, the test also shows potential for identifying signals linked to pulmonary fibrosis (image credit: iStock)

Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively

Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.